Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Brazil / NCT04947605
Active, not recruiting Observational

Epidemiological Landscape of Cervical Cancer in Latin America

NCT04947605 · tracked via the Priya Life Science Brazil tracker
Sponsor
Latin American Cooperative Oncology Group
Phase
Observational
Started
2021-11-04
Last updated
2026-08-27

Condition(s) studied

Uterine Cervical Neoplasms

Study summary

A portrait of clinical and epidemiological aspects of cervical cancer in Latin America is required to understand the high frequency of cervical cancer despite the existence of effective preventive tools. A better understanding of the current situation of this scenario will provide a valuable groundwork for the development of national and cooperative programs to improve cervical cancer prevention and treatment.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Women \> 18 years. * Histologically proven cervical carcinoma * Diagnosis of carcinoma of the cervix since January 2018 or newly diagnosis or recurrent disease during the period of study recruitment. * Any histology of cervical cancer at time of diagnosis. * FIGO stage IB2-IVA * Have available and adequate medical records for data collection * Accept to participate in the project and sign the informed consent (if applicable) Exclusion Criteria: * FIGO stage I and IB1 * Non-invasive cervical cancer * Synchronous tumor or second primary tumor in the last five years (exception for thyroid cancer or skin cancer non melanoma)

Primary outcome measure(s)

Trial sites (12)

FacilityCityRegionStatus
Sanatorio de La Mujer Rosario Santa Fe Province
Centro Medico San Roque Exelsus San Miguel de Tucumán Tucumán Province
CRIO - Centro Regional Integrado de Oncologia Fortaleza Ceará
Hospital Erasto Gaertner Curitiba Paraná
INCA - Instituto Nacional de Câncer Rio de Janeiro Rio de Janeiro
CPO - Centro de Pesquisa em Oncologia do Hospital São Lucas da PUCRS Porto Alegre Rio Grande do Sul
Hospital de Amor de Barretos Barretos São Paulo
ICESP - Instituto do Câncer do Estado de São Paulo São Paulo São Paulo
Pérola Centro de Pesquisa em Oncologia São Paulo São Paulo
BP - A Beneficência Portuguesa de São Paulo São Paulo São Paulo
INCART - Instituto Nacional del Cáncer Rosa Emilia Sánchez Pérez de Tavares Santo Domingo Grande Santo Domingo
Instituto Nacional de Enfermedades Neoplásicas (INEN) Lima Peru

More Latin American Cooperative Oncology Group trials in Brazil

Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer Active, not recruiting
Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell Carcinoma Starting soon
A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin America Active, not recruiting
Oncogeriatric Screening and Evaluation Program Starting soon
Epidemiological Profile of Patients With IDH-Mutant Diffuse Gliomas Diagnosed From 2021 in Brazil Starting soon

Other trials for the same condition

Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04947605 on ClinicalTrials.gov ↗ ← All trials in Brazil